Last reviewed · How we verify

Terbutaline sulphate

AstraZeneca · Phase 3 active Small molecule

Terbutaline sulphate is a Beta-2 adrenergic receptor agonist Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Asthma, Chronic obstructive pulmonary disease (COPD). Also known as: Terbutaline sulphate powder for inhalation, 0.5 mg (metered dose) terbutaline per inhalation, Terbutaline sulphate powder for inhalation, 0.4 mg (delivered dose) terbutaline per inhalation.

Terbutaline sulphate is a beta-2 adrenergic receptor agonist that works by stimulating the beta-2 receptors in the lungs to cause bronchodilation.

Terbutaline sulphate is a beta-2 adrenergic receptor agonist that works by stimulating the beta-2 receptors in the lungs to cause bronchodilation. Used for Asthma, Chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameTerbutaline sulphate
Also known asTerbutaline sulphate powder for inhalation, 0.5 mg (metered dose) terbutaline per inhalation, Terbutaline sulphate powder for inhalation, 0.4 mg (delivered dose) terbutaline per inhalation
SponsorAstraZeneca
Drug classBeta-2 adrenergic receptor agonist
TargetBeta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

This leads to relaxation of bronchial smooth muscle, resulting in increased airflow to the lungs and relief of bronchospasm symptoms. Terbutaline sulphate is a selective beta-2 agonist, which means it has a higher affinity for beta-2 receptors than beta-1 receptors, reducing the risk of cardiac side effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Terbutaline sulphate

What is Terbutaline sulphate?

Terbutaline sulphate is a Beta-2 adrenergic receptor agonist drug developed by AstraZeneca, indicated for Asthma, Chronic obstructive pulmonary disease (COPD).

How does Terbutaline sulphate work?

Terbutaline sulphate is a beta-2 adrenergic receptor agonist that works by stimulating the beta-2 receptors in the lungs to cause bronchodilation.

What is Terbutaline sulphate used for?

Terbutaline sulphate is indicated for Asthma, Chronic obstructive pulmonary disease (COPD).

Who makes Terbutaline sulphate?

Terbutaline sulphate is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is Terbutaline sulphate also known as anything else?

Terbutaline sulphate is also known as Terbutaline sulphate powder for inhalation, 0.5 mg (metered dose) terbutaline per inhalation, Terbutaline sulphate powder for inhalation, 0.4 mg (delivered dose) terbutaline per inhalation.

What drug class is Terbutaline sulphate in?

Terbutaline sulphate belongs to the Beta-2 adrenergic receptor agonist class. See all Beta-2 adrenergic receptor agonist drugs at /class/beta-2-adrenergic-receptor-agonist.

What development phase is Terbutaline sulphate in?

Terbutaline sulphate is in Phase 3.

What are the side effects of Terbutaline sulphate?

Common side effects of Terbutaline sulphate include Tremors, Nervousness, Headache, Palpitations, Dizziness.

What does Terbutaline sulphate target?

Terbutaline sulphate targets Beta-2 adrenergic receptor and is a Beta-2 adrenergic receptor agonist.

Related